AVXL—(-33%/PM)—misses phase-2/3 co-primary endpoint in Rett syndrome: https://www.globenewswire.com/news-release/2024/01/02/2802638/29248/en/Anavex-Life-Sciences-Provides-an-Update-on-Rett-Syndrome-Program.html